Kura Oncology, Inc. 8-K

What Happened

• Kura Oncology, Inc. filed an 8-K on June 4, 2026 reporting results of its June 4, 2026 Annual Meeting. The Board had amended the 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan on April 9, 2026 (subject to shareholder approval). Shareholders approved those amendments at the meeting.
• The amendments increase authorized shares by 6,500,000 for the Amended 2014 Plan and by 2,500,000 for the Amended ESPP. The record date for the meeting was April 6, 2026 (88,762,704 shares outstanding) and 69,778,580 shares were present virtually or by proxy.

Key Details

• Amended 2014 Equity Incentive Plan: Approved — For 48,402,820; Against 10,099,296; Abstain 178,916; Broker non-votes 11,097,548.
• Amended 2015 ESPP: Approved — For 58,306,174; Against 213,434; Abstain 161,424; Broker non-votes 11,097,548.
• Director elections: Diane Parks, Mary T. Szela and Michael J. Vasconcelles, M.D. were elected as Class III directors (votes: Parks 44,060,724 For; Szela 38,859,502 For; Vasconcelles 58,169,894 For).
• Other matters: Ernst & Young LLP was ratified as independent auditor (For 69,385,497). Advisory Say-on-Pay passed (For 48,783,834) and shareholders indicated a 1-year frequency for future advisory votes; the Board will hold annual say-on-pay votes.

Why It Matters

• The share increases for the equity plan and ESPP give Kura more stock available for employee compensation, option grants and employee purchase programs, which can affect dilution and future share-based compensation expense. Investors should note the specific share increases (6.5M and 2.5M).
• Re-election of the board slate and ratification of the auditor reflect shareholder support for current governance. Annual say-on-pay votes mean the company will continue regular, yearly shareholder advisory votes on executive compensation.